【4591】リボミック
創薬。分子標的薬を開発。大株主に大塚製薬。
類似企業:
【業界1位】
小野薬品工業
【業界1位】
小野薬品工業
売上高
営業利益
経常利益
当期利益
業績予想修正
対前回修正率
当初予想比較
決算期 | 日付 | 予・実 | 売上高 (百万円) | 対前回 | 営業利益 (百万円) | 対前回 | 経常利益 (百万円) | 対前回 | 当期利益 (百万円) | 対前回 |
---|---|---|---|---|---|---|---|---|---|---|
2025.03 | 2025/02/12 | Q3予 | 2 | → | -1,436 | → | -1,403 | → | -1,404 | → |
2025.03 | 2024/11/12 | Q2予 | 2 | → | -1,436 | → | -1,403 | → | -1,404 | → |
2025.03 | 2024/08/09 | Q1予 | 2 | ↑ | -1,436 | → | -1,403 | ↑ | -1,404 | ↑ |
2025.03 | 2024/05/14 | 当初予 | 1 | - | -1,436 | - | -1,404 | - | -1,405 | - |
2024.03 | 2024/05/14 | 実 | 0 | - | -1,116 | ↑ | -982 | ↑ | -1,024 | ↑ |
2024.03 | 2024/02/13 | Q3予 | - | - | -1,366 | → | -1,249 | → | -1,250 | → |
2024.03 | 2023/11/13 | Q2予 | - | - | -1,366 | → | -1,249 | → | -1,250 | → |
2024.03 | 2023/08/10 | Q1予 | - | - | -1,366 | → | -1,249 | → | -1,250 | → |
2024.03 | 2023/05/12 | 当初予 | - | - | -1,366 | - | -1,249 | - | -1,250 | - |
2023.03 | 2023/05/12 | 実 | 65 | → | -1,786 | ↑ | -1,649 | ↑ | -1,653 | ↑ |
2023.03 | 2023/02/10 | Q3予 | 65 | → | -2,402 | → | -2,293 | → | -2,294 | → |
2023.03 | 2022/11/11 | Q2予 | 65 | → | -2,402 | → | -2,293 | → | -2,294 | → |
2023.03 | 2022/08/09 | Q1予 | 65 | → | -2,402 | → | -2,293 | → | -2,294 | → |
2023.03 | 2022/05/13 | 当初予 | 65 | - | -2,402 | - | -2,293 | - | -2,294 | - |
2022.03 | 2022/05/13 | 実 | 80 | → | -1,748 | → | -1,635 | → | -1,684 | → |
2022.03 | 2022/05/09 | 修正予 | 80 | → | -1,748 | ↑ | -1,635 | ↑ | -1,684 | ↑ |
2022.03 | 2022/02/14 | Q3予 | 80 | → | -2,495 | → | -2,391 | → | -2,393 | → |
2022.03 | 2021/11/09 | Q2予 | 80 | → | -2,495 | → | -2,391 | → | -2,393 | → |
2022.03 | 2021/08/06 | Q1予 | 80 | → | -2,495 | → | -2,391 | → | -2,393 | → |
2022.03 | 2021/05/13 | 当初予 | 80 | - | -2,495 | - | -2,391 | - | -2,393 | - |
2021.03 | 2021/05/13 | 実 | 91 | → | -1,239 | ↑ | -1,184 | ↑ | -1,187 | ↑ |
2021.03 | 2021/02/12 | Q3予 | 91 | ↓ | -1,274 | ↑ | -1,216 | ↑ | -1,218 | ↑ |
2021.03 | 2020/11/12 | Q2予 | 118 | → | -1,561 | → | -1,484 | → | -1,485 | → |
2021.03 | 2020/08/07 | Q1予 | 118 | → | -1,561 | → | -1,484 | → | -1,485 | → |
2021.03 | 2020/05/14 | 当初予 | 118 | - | -1,561 | - | -1,484 | - | -1,485 | - |
2020.03 | 2020/05/14 | 実 | 121 | ↑ | -914 | ↑ | -853 | ↑ | -855 | ↑ |
2020.03 | 2020/02/07 | Q3予 | 116 | → | -1,055 | → | -987 | → | -988 | → |
2020.03 | 2019/11/12 | Q2予 | 116 | → | -1,055 | → | -987 | → | -988 | → |
2020.03 | 2019/08/09 | Q1予 | 116 | → | -1,055 | → | -987 | → | -988 | → |
2020.03 | 2019/05/14 | 当初予 | 116 | - | -1,055 | - | -987 | - | -988 | - |
2019.03 | 2019/05/14 | 実 | 7 | → | -928 | ↑ | -835 | ↑ | -836 | ↑ |
2019.03 | 2019/03/20 | 修正予 | 7 | ↑ | -947 | ↑ | -854 | ↑ | -855 | ↑ |
2019.03 | 2019/02/13 | Q3予 | 5 | → | -950 | → | -857 | → | -858 | → |
2019.03 | 2019/01/28 | 修正予 | 5 | ↑ | -950 | ↑ | -857 | ↑ | -858 | ↑ |
2019.03 | 2018/11/13 | Q2予 | 4 | → | -1,090 | → | -997 | → | -998 | → |
2019.03 | 2018/08/09 | Q1予 | 4 | → | -1,090 | → | -997 | → | -998 | → |
2019.03 | 2018/05/14 | 当初予 | 4 | - | -1,090 | - | -997 | - | -998 | - |
2018.03 | 2018/05/14 | 実 | 64 | ↓ | -899 | ↑ | -751 | ↑ | -753 | ↑ |
2018.03 | 2018/02/13 | Q3予 | 65 | → | -1,002 | → | -873 | → | -875 | → |
2018.03 | 2017/11/09 | Q2予 | 65 | → | -1,002 | → | -873 | → | -875 | → |
2018.03 | 2017/08/08 | Q1予 | 65 | → | -1,002 | → | -873 | → | -875 | → |
2018.03 | 2017/05/12 | 当初予 | 65 | - | -1,002 | - | -873 | - | -875 | - |
2017.03 | 2017/05/12 | 実 | 93 | ↓ | -785 | → | -658 | ↑ | -646 | ↑ |
2017.03 | 2017/02/13 | Q3予 | 95 | → | -785 | → | -719 | → | -720 | → |
2017.03 | 2016/05/12 | 当初予 | 95 | - | -785 | - | -719 | - | -720 | - |
2016.03 | 2016/05/12 | 実 | 121 | ↑ | -532 | ↓ | -322 | ↑ | -323 | ↑ |
2016.03 | 2016/02/09 | Q3予 | 119 | ↑ | -474 | ↓ | -451 | ↓ | -452 | ↓ |
2016.03 | 2015/11/06 | Q2予 | 0 | ↓ | - | - | 0 | ↑ | 0 | ↑ |
2016.03 | 2015/08/13 | Q1予 | 524 | → | -120 | → | -86 | → | -96 | → |
2016.03 | 2015/05/14 | 当初予 | 524 | - | -120 | - | -86 | - | -96 | - |
2015.03 | 2015/05/14 | 実 | 479 | ↓ | 6 | ↓ | 13 | ↓ | 10 | ↓ |
2015.03 | 2015/02/09 | Q3予 | 508 | → | 32 | → | 50 | → | 45 | → |
2015.03 | 2014/11/07 | 当初予 | 508 | - | 32 | - | 50 | - | 45 | - |